• Explore /
  • Poster
  • / An open-label, phase II study of rucaparib, a PARP inhibitor, in HER2- metastatic breast cancer patients with high genomic loss of heterozygosity: RUBY.

An open-label, phase II study of rucaparib, a PARP inhibitor, in HER2- metastatic breast cancer patients with high genomic loss of heterozygosity: RUBY.

Abstract Poster

Authors

null

Anne Patsouris

Institute of West Cancerology Paul Papin, Angers, France

Anne Patsouris , Cecile Vicier , Loic Campion , Wilfried Gouraud , Marta Jimenez , Veronica Pezzella , Andrea Loehr , Mitch Raponi , Ivan Bieche , Celine Callens , Fabrice Andre

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

Hormone Receptor-Positive

Clinical Trial Registration Number

NCT02505048

Citation

J Clin Oncol 35, 2017 (suppl; abstr TPS1117)

DOI

10.1200/JCO.2017.35.15_suppl.TPS1117

Abstract #

TPS1117

Poster Bd #

103b

Abstract Disclosures

Similar Posters

First Author: Anne Patsouris

First Author: Wassim Abida

First Author: Ruben Raychaudhuri

First Author: Severine Guiu Lahaye